EMGLIF LMXR 10/5/1000MG TAB

EMGLIF LMXR is a triple-action combination tablet designed for comprehensive diabetes management. Each tablet contains empagliflozin 10mg, linagliptin 5mg, and metformin HCl 1000mg—three potent antidiabetic agents working synergistically to improve glycemic control. Empagliflozin helps reduce blood glucose by promoting urinary glucose excretion, while linagliptin enhances insulin secretion by inhibiting DPP-4 enzymes. Metformin improves insulin sensitivity and reduces hepatic glucose production. This triple combination addresses multiple pathways of hyperglycemia, making it ideal for patients requiring intensified therapy. EMGLIF LMXR is suitable for adults with type 2 diabetes mellitus when monotherapy or dual therapy proves insufficient. The extended-release formulation ensures sustained drug delivery throughout the day, supporting consistent blood sugar management with convenient once-daily dosing. Always follow your healthcare provider's guidance regarding dosage and duration. Store in a cool, dry place away from direct sunlight.